GnRH抗体:化学和配方的比较分析与临床安全性和有效性的影响
Shikha Patel1, Bhagawati Saxena2, Priti Mehta1
1Department of Pharmaceutical Analysis, Institute of Pharmacy, Nirma University, Ahmedabad 382481, India.
Pharmaceuticals (Basel, Switzerland)
|January 25, 2025
概括
GnRH抗体通过阻断性腺激素释放激素受体 (GnRH-R) 为生殖癌和荷尔蒙依赖性疾病提供了一种革命性的治疗方法. 这些先进的疗法比传统方法提供更快的作用和更好的安全性.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 淋巴激素释放激素受体 (GnRH-R) 的过度表达与生殖性恶性瘤的进展有关.
- GnRH对抗剂代表了对荷尔蒙依赖性疾病的显著治疗进展.
研究的目的:
- 审查GnRH在生殖生理学和疾病中的药理作用.
- 强调第三代和第四代GnRH对抗剂的结构进步.
- 分析GnRH抗体的配方,药理动力学,疗效和安全性.
主要方法:
- 关于GnRH抗剂的文献综述.
- 对已批准的GnRH抗体 (Cetrorelix,Ganirelix,Abarelix,Degarelix,Teverelix) 的分析.
- 对临床前景和未来研究方向的评估.
主要成果:
- GnRH抗剂通过阻断GnRH-R.提供快速,可逆的淋巴激素抑制.
- 这些对抗剂防止激素爆发,作用更快,心血管风险低于激动剂.
- 像Cetrorelix和Ganirelix这样的经批准的抗剂主导了ART,而Degarelix和Abarelix在前列腺癌中显示出有前途.
结论:
- GnRH对抗剂对于晚期前列腺癌,子宫内膜异位症,子宫纤维瘤和ART具有革命性作用.
- 像Teverelix这样的下一代抗剂提供了更好的疗效和安全性.
- 对GnRH抗剂的进一步研究可以导致更安全,更有效的治疗复杂的荷尔蒙疾病.
相关概念视频
Bioequivalence: Overview
915
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
915
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.5K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.5K
Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.1K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
803
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
803


